Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, B. Riley Financial Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its target price raised by research analysts at B. Riley Financial from $26.00 to $31.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price target would suggest a potential upside of 38.89% from the company’s previous close.

ETON has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Craig Hallum upped their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen downgraded Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, HC Wainwright upped their price objective on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON opened at $22.32 on Friday. Eton Pharmaceuticals has a one year low of $11.09 and a one year high of $23.00. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.63 and a quick ratio of 1.25. The company has a market cap of $598.62 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. The firm has a 50 day simple moving average of $16.72 and a 200 day simple moving average of $17.38.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, March 19th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The company had revenue of $21.28 million for the quarter, compared to the consensus estimate of $20.58 million. Eton Pharmaceuticals had a negative return on equity of 2.66% and a negative net margin of 5.75%. Research analysts predict that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC raised its position in Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Eton Pharmaceuticals by 34.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after buying an additional 45,341 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Eton Pharmaceuticals by 49.1% in the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after buying an additional 31,596 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Eton Pharmaceuticals by 33.1% in the second quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company’s stock valued at $328,000 after buying an additional 5,734 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 98.8% during the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock worth $8,450,000 after acquiring an additional 294,617 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.